AB Science S.A. (OTCMKTS:ABSCF – Get Free Report) fell 5.7% on Tuesday . The stock traded as low as $1.00 and last traded at $1.00. 1,000 shares were traded during trading, a decline of 97% from the average session volume of 39,925 shares. The stock had previously closed at $1.06.
AB Science Trading Down 5.7 %
The firm’s fifty day moving average price is $1.06 and its two-hundred day moving average price is $2.06.
AB Science Company Profile
AB Science SA, a clinical-stage company, designs and develops novel drugs to various diseases with high unmet medical needs for inflammatory diseases, pathologies affecting peripheral and central nervous system, and cancers in France. The company’s lead compound is the masitinib, a tyrosine kinase inhibitor which is in Phase III clinical trials for the treatment of amyotrophic lateral sclerosis, indolent systemic mastocytosis, severe asthma, progressive forms of multiple sclerosis, first line pancreatic cancer with pain, alzheimer’s disease, and metastatic castrate-resistant prostate cancer, as well as in Phase II clinical trial to treat Covid-19.
Featured Articles
- Five stocks we like better than AB Science
- Why Understanding Call Option Volume is Essential to Successful Options Trading
- Goldman Sachs Earnings Reveal Market Moves Investors Can’t Ignore
- What to Know About Investing in Penny Stocks
- AMD Gains Momentum With AI: Can It Beat Expectations?
- What is a Dividend King?
- Lithium Grab: 2 Lithium Stocks That Could Be Takeover Targets
Receive News & Ratings for AB Science Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AB Science and related companies with MarketBeat.com's FREE daily email newsletter.
